应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NXTS Nexentis Technologies Inc
未开盘 06-25 16:00:00 EDT
5.20
-0.73
-12.31%
盘后
5.11
-0.09
-1.76%
19:58 EDT
最高
5.91
最低
5.01
成交量
28.36万
今开
5.73
昨收
5.93
日振幅
15.18%
总市值
379.76万
流通市值
220.03万
总股本
73.03万
成交额
154.71万
换手率
67.01%
流通股本
42.31万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Nexentis Technologies宣布Mitocarex与Boltz达成合作,共同推进AI驱动的SLC小分子药物发现
美股速递 · 06-22
Nexentis Technologies宣布Mitocarex与Boltz达成合作,共同推进AI驱动的SLC小分子药物发现
Nexentis Technologies旗下Mitocarex发现更多符合Mitoline规则的Slc蛋白
美股速递 · 06-17
Nexentis Technologies旗下Mitocarex发现更多符合Mitoline规则的Slc蛋白
Nexentis Technologies子公司Mitocarex完成人类Slc转运蛋白的全面分析
美股速递 · 06-17
Nexentis Technologies子公司Mitocarex完成人类Slc转运蛋白的全面分析
Nexentis 宣布 Mitocarex Bio 达成关键研发里程碑,在迈向临床前开发的道路上生成显著优化的先导化合物
美股速递 · 05-18
Nexentis 宣布 Mitocarex Bio 达成关键研发里程碑,在迈向临床前开发的道路上生成显著优化的先导化合物
公司概况
公司名称:
Nexentis Technologies Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Nexentis Technologies Inc.于2009年4月1日在特拉华州注册成立,并于2023年11月10日在内华达州重新注册成立。该公司专注于太阳能项目和肿瘤生物技术领域的可持续运营。通过其全资子公司MitoCareX Bio Ltd.,它是一家靶向线粒体载体家族用于癌症和炎症性代谢疾病的药物发现公司,同时其Solterra业务在欧洲开发可再生能源项目。
发行价格:
--
{"stockData":{"symbol":"NXTS","market":"US","secType":"STK","nameCN":"Nexentis Technologies Inc","latestPrice":5.2,"timestamp":1782417600000,"preClose":5.93,"halted":0,"volume":283564,"hourTrading":{"tag":"盘后","latestPrice":5.1084,"preClose":5.2,"latestTime":"19:58 EDT","volume":12186,"amount":62692.0738,"timestamp":1782431930664,"change":-0.0916,"changeRate":-0.017615,"amplitude":0.043385},"delay":0,"changeRate":-0.1231028667790893,"floatShares":423136,"shares":730309,"eps":-31.468225,"marketStatus":"未开盘","change":-0.73,"latestTime":"06-25 16:00:00 EDT","open":5.73,"high":5.91,"low":5.01,"amount":1547060.3612696,"amplitude":0.151771,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-31.468225,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782460800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":5.93,"preHourTrading":{"tag":"盘前","latestPrice":5.85,"preClose":5.93,"latestTime":"09:29 EDT","volume":26267,"amount":155337.16469879998,"timestamp":1782394154199,"change":-0.08,"changeRate":-0.013491,"amplitude":0.046358},"postHourTrading":{"tag":"盘后","latestPrice":5.1084,"preClose":5.2,"latestTime":"19:58 EDT","volume":12186,"amount":62692.0738,"timestamp":1782431930664,"change":-0.0916,"changeRate":-0.017615,"amplitude":0.043385},"volumeRatio":0.020112},"requestUrl":"/m/hq/s/NXTS/wiki","defaultTab":"wiki","newsList":[{"id":"1158947150","title":"Nexentis Technologies宣布Mitocarex与Boltz达成合作,共同推进AI驱动的SLC小分子药物发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1158947150","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158947150?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:24","pubTimestamp":1782131058,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc宣布,其旗下Mitocarex部门已与Boltz公司达成合作,将共同利用人工智能技术推进SLC(溶质载体)小分子药物的发现工作。此次合作旨在结合双方在生物技术与人工智能算法领域的专长,加速针对SLC靶点的新药研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130882652","title":"Nexentis Technologies旗下Mitocarex发现更多符合Mitoline规则的Slc蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=1130882652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130882652?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:34","pubTimestamp":1781696067,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc. 宣布,其旗下公司Mitocarex在研究中取得新进展,识别出了更多符合“Mitoline”规则集的溶质载体蛋白。这一发现有望为基于该技术平台的新药研发提供更广阔的目标选择空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119676886","title":"Nexentis Technologies子公司Mitocarex完成人类Slc转运蛋白的全面分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1119676886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119676886?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:33","pubTimestamp":1781695994,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc的子公司Mitocarex宣布,已完成对人类溶质载体(Slc)转运蛋白家族的全面分析。这项研究旨在深入探索该蛋白家族在细胞代谢和药物转运中的关键作用,为后续的药物靶点发现和新型疗法开发奠定重要的科学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171654842","title":"Nexentis 宣布 Mitocarex Bio 达成关键研发里程碑,在迈向临床前开发的道路上生成显著优化的先导化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1171654842","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171654842?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:33","pubTimestamp":1779111196,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc 近日宣布,其旗下的Mitocarex Bio项目已成功达成一项关键的研发里程碑。该项目在通往临床前开发的道路上取得了重要进展,成功生成了一种经过显著优化的先导化合物分子。这一突破标志着该候选药物在早期开发阶段迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://nexentistech.com","stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.1429},{"period":"6month","weight":-0.6654},{"period":"1year","weight":-0.915},{"period":"ytd","weight":-0.5578}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nexentis Technologies Inc.于2009年4月1日在特拉华州注册成立,并于2023年11月10日在内华达州重新注册成立。该公司专注于太阳能项目和肿瘤生物技术领域的可持续运营。通过其全资子公司MitoCareX Bio Ltd.,它是一家靶向线粒体载体家族用于癌症和炎症性代谢疾病的药物发现公司,同时其Solterra业务在欧洲开发可再生能源项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.878993},{"month":2,"riseRate":0.2,"avgChangeRate":-0.227601},{"month":3,"riseRate":0.2,"avgChangeRate":-0.180927},{"month":4,"riseRate":0.4,"avgChangeRate":-0.01097},{"month":5,"riseRate":0.4,"avgChangeRate":-0.066643},{"month":6,"riseRate":0,"avgChangeRate":-0.189582},{"month":7,"riseRate":0.8,"avgChangeRate":0.094778},{"month":8,"riseRate":0.2,"avgChangeRate":-0.144178},{"month":9,"riseRate":0,"avgChangeRate":-0.308698},{"month":10,"riseRate":0,"avgChangeRate":-0.105439},{"month":11,"riseRate":0,"avgChangeRate":-0.153815},{"month":12,"riseRate":0.4,"avgChangeRate":-0.183817}],"exchange":"NASDAQ","name":"Nexentis Technologies Inc","nameEN":"Nexentis Technologies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nexentis Technologies Inc(NXTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nexentis Technologies Inc(NXTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nexentis Technologies Inc,NXTS,Nexentis Technologies Inc股票,Nexentis Technologies Inc股票老虎,Nexentis Technologies Inc股票老虎国际,Nexentis Technologies Inc行情,Nexentis Technologies Inc股票行情,Nexentis Technologies Inc股价,Nexentis Technologies Inc股市,Nexentis Technologies Inc股票价格,Nexentis Technologies Inc股票交易,Nexentis Technologies Inc股票购买,Nexentis Technologies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nexentis Technologies Inc(NXTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nexentis Technologies Inc(NXTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}